CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Malignancy and Kidney Transplant: Core Curriculum 2026.
Malignancy and Kidney Transplant: Core Curriculum 2026.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
与免疫功能正常人群相比,肾移植受者患癌风险至少高出一倍。癌症现已成为肾移植受者的第二大死因。移植候选者和受者在慢性疾病和免疫抑制背景下生存时间延长,癌症风险随之上升,尤其包括皮肤癌、肾癌、淋巴瘤和浆细胞疾病。鉴于肾移植患者癌症照护复杂,以及靶向治疗、免疫检查点抑制剂和 CAR-T 细胞等新型癌症疗法不断出现,肾脏科医生越来越需要了解并管理相关风险,优化诊断和治疗。肾移植背景下癌症筛查和管理最好由多学科团队完成,团队应包括具备相关知识的肾脏科医生、肿瘤科医生和患者。在本核心课程中,作者通过一系列临床病例回顾常见移植前后癌症及其管理策略。
Kidney transplant recipients are at least twice as likely to develop cancer compared with immunocompetent people. Cancer is now the second leading cause of death in kidney transplant recipients. Candidates and recipients are living longer with chronic conditions and immunosuppression, which increases the risk of cancers, especially skin and kidney cancers, lymphoma, and plasma cell dyscrasias.
Given the complexities associated with the care of transplant patients with cancer, along with the advent of novel cancer therapies that include targeted and immunotherapies (ie, immune checkpoint inhibitors and CAR-T cells), there is a growing need for nephrologists to understand and manage the associated risks and optimize diagnosis and treatment.
The screening and management of cancer in the setting of kidney transplantation is best accomplished by a multidisciplinary team, involving knowledgeable nephrologists, oncologists, and patients. In this Core Curriculum, we review common pretransplant and posttransplant cancers and management strategies through a series of clinical cases.
MEMBER ACCOUNT
登录成功会直接打开下一页。